www.i-canadianpharmacy.com
- US Toll free:
- Regular US:
- UK:
- Categories list
-
- Alcoholism
- Alzheimer's And Parkinson's
- Analgesics
- Anti-inflammatories
- Antiallergic
- Antibiotics
- Anticonvulsants
- Antidepressants
- Antifungals
- Antiparasitic
- Antivirals
- Arthritis
- Asthma
- Birth Control
- Cancer
- Cardiovascular Diseases
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Care
- Gastrointestinal Tract
- HIV
- Hypertension
- Men's Health
- Mental Disorders
- Migraine
- Muscle Relaxants
- Neurological Disorders
- Obesity
- Osteoporosis
- Respiratory Tract
- Skin Care
- Surgery
- Urinary Tract
- Women's Health
Generic Lamivudine zidovudine - Combivir, Epivir, Retrovir, Depakote, Fansidar, Rebetol, Sustiva, Zerit
Generic Combivir
Generic Combivir is in a group of medicines called reverse transcriptase inhibitors. It is used for treating HIV infection in combination with other medicines.
$1.44
Buy now!
$1.73
Buy now!
$1.17
Buy now!
Generic Depakote
Divalproex sodium affects chemicals in the body that may be involved in causing seizures.
$0.62
Buy now!
Generic Fansidar
Generic Fansidar is used for treating and preventing malaria when other medicines (eg, chloroquine) are not effective or appropriate.
$0.71
Buy now!
Generic Rebetol
Treating hepatitis C infection in certain patients when used in combination with interferon.
$7.50
Buy now!
Generic Sustiva
Generic Sustiva is used for treating HIV infection in combination with other medicines. If this medicine is taken alone to treat HIV, it may stop working.
$3.33
Buy now!
$0.83
Buy now!
Choose Your language:
- Testimonials
-
You guys are excellent. Please accept my blessing to your business. )))))))))))))))))))))))))))))))
Read more »
- News
-
- FDA approved Tadalafil medication for the treatment of erectile dysfunction accompanied with primary and secondary symptoms of benign prostatic hyperplasia (BPH) in men above 45 years.
- Considering the information of three randomized, multicenter, double, blind clinical studies and a retrospective analysis of the medical documentation, FDA approved on October 7, 2011 Tadalafil medication for the treatment of erectile dysfunction accompanied with primary and secondary symptoms of benign prostatic hyperplasia (BPH) in men above 45 years
- The forming, development and monitoring of the pharmaceutical market in USA in September 2011
- In spite of low rates and stagnation of industrial development, the pharmaceutical market shows a dynamical growth
- Sildenafil citrate and pulmonary arterial hypertension
- Pulmonary arterial hypertension Definition “pulmonary arterial hypertension” is related to a group of diseases characterized by: - Progressive increase in pulmonary vascular resistance; - Reduction in pulmonary bloodflow; - High pulmonary artery pressure; - Contractility of the heart right ventricle; - Right ventricular failure
- Fruit and vegetables do not reduce overall cancer risk, review concludes
- Eating lots of fruit and vegetables will do little to reduce your risk of developing cancer, according to a review of a decade of research involving more than a million people
- Common painkillers could be linked to male reproductive disorder
- The use of mild painkillers, such as paracetamol, in pregnancy – previously considered harmless to the baby in the womb – could be a major factor in the rise of male reproductive disorders, according to a study
-
- Lupin Launches Generic Combivir Tablets - RTT News
- Moneycontrol
- Lupin, Aurobindo get USFDA nod for HIV drug - Economic Times
- Lupin, Aurobindo get USFDA nod for HIV drugEconomic TimesLamivudine-Zidovudine combination is indicated along with other antiretroviral agents for the treatment of HIV-1 infection
- Lupin launches generic Combivir tablets - pharmabiz.com
- Lupin launches generic Combivir tabletspharmabiz
- LANDMARK HIV DRUG'S PATENT EXPIRES TODAY - U-T San Diego
- LANDMARK HIV DRUG'S PATENT EXPIRES TODAYU-T San DiegoThe FDA approved Combivir (lamivudine/zidovudine) in 1997, greatly changing the treatment of HIV/AIDS
 |
Bookmark this site |
|---|
 |
Subscribe to the News |
|---|
